Inflammatory Response as a Prognostic Factor of Recurrence of Atrial Fibrillation After Ablation

Assessment of Course of Inflammatory Biomarkers Concentrations After Pulmonary Veins Isolation as a Prognostic Factor of Atrial Fibrillation Treatment Effectiveness (ACtIVE-AF Study)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02844959

Acronym

ACtIVE-AF

Enrollment

120

Registered

2016-07-26

Start date

2016-07-31

Completion date

2018-07-31

Last updated

2016-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation, Biomarkers, Inflammatory Response, C-reactive protein, FGF2, MMP8, troponin I, body temperature

Brief summary

The aim of this study is to evaluate inflammatory response as a prognostic factor of atrial fibrillation recurrency after ablation. Inflammatory response will be assessed by double measurement of C-reactive protein, fibroblast growth factor 2 (FGF2), matrix metallopeptidase 8 (MMP8) and body temperature. Dynamics of change of troponin I will be measured additionally. After ablation each patient will be monitored with ECG telemonitoring system for 7 days.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* signed consent; * criteria for ablation of atrial fibrillation.

Exclusion criteria

* previous pulmonary veins isolation; * ablation other than pulmonary veins isolation during the procedure; * atrial fibrillation at the beginning of ablation procedure; * usage of 'single shot' devices.

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation within the first 7 days after ablation	within the first 7 days after ablation

Secondary

Measure	Time frame
Atrial fibrillation within 6 months after ablation	6 months

Countries

Poland

Contacts

Primary ContactMichał Peller, MD

michalpeller@gmail.com694 914 962

Backup ContactKrzysztof Ozierański, MD

krzysztof.ozieranski@gmail.com509 996 947

Outcome results